A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K.sub.3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K.sub.3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
This application claims priority to U.S. Ser. No. 60/295,025, entitled NONTOXIC POTENTIATION/SENSITIZATION OF CANCER THERAPY BY SUPPLEMENTARY TREATMENT WITH COMBINED VITAMINS C AND K.sub.3, filed Jun. 1, 2001.
